Skip to main content

Eli Lilly — Portfolio, Page 4

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

158
Companies
$7.3B
Total invested
$55.2M
Avg. check
20
Industries
Biotechnology 22Health Care 14Life Science 8Therapeutics 8Medical 8Biopharma 7+14 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 7396 of 158
Juvena Therapeutics
January 2026

Juvena Therapeutics develops tissue-restorative biologics to address chronic muscle and age-related conditions.

Biopharma · Palo Alto$33.5M Series B
Rimidi
January 2023

Rimidi is a health IT platform that enables virtual, personalized management of cardiometabolic diseases.

Health Care · Atlanta$5.0M Venture - Series Unknown
Fountain Therapeutics
November 2021

Fountain Therapeutics is discovering and developing treatments for aging-associated diseases.

Biotechnology · San Francisco$15.0M Series A
Rezo Therapeutics
November 2022

Rezo Therapeutics identifies targets and therapies by combining distinct, unbiased technologies with artificial intelligence.

Artificial Intelligence (AI) · South San Francisco$78.0M Series A
Gate Bioscience
November 2025

Gate Bioscience is a biotechnology company that specializes in a small molecule modality to treat biology’s intractable diseases.

Biotechnology · Brisbane$65.0M Series B
Beta Bionics
November 2024

Beta Bionics is a biotechnology company that provides software to reduce the burden of diabetes care.

Biotechnology · Irvine$60.0M Series E
ViaNautis
November 2023

ViaNautis is at the forefront of developing novel medications capable of crossing biological barriers.

Biopharma · Cambridge$24.6M Series A
NextCure
November 2025

NextCure is a biopharmaceutical company focused on discovering and developing next generation immuno-oncology-based drugs.

Biopharma · Beltsville$21.5M Post-IPO Equity
Affinia Therapeutics
October 2025

Affinia Therapeutics is a biotechnology company developing transformative AAV gene therapies for people with rare and prevalent diseases.

Biotechnology · Waltham$40.0M Series C
Cedilla Therapeutics
October 2021

Cedilla Therapeutics is a biotechnology company that develops targeted small molecules for the treatment of cancer and other diseases.

Biotechnology · Cambridge$25.0M Series B
Verge Genomics
October 2024

Verge Genomics uses machine learning and human genomics to accelerate drug discovery.

Artificial Intelligence (AI) · San FranciscoSeries C
Sunbird Bio
October 2024

Sunbird Bio is a diagnostics platform developer that aims to give molecular diagnostics with faster outcomes.

Biotechnology · Singapore$14.0M Venture - Series Unknown
BreezeBio
February 2026

BreezeBio is a biotechnology business that creates genetic therapies using precision, non-viral delivery across clinically important tissues

Artificial Intelligence (AI) · Brisbane$60.0M Series B
TRex Bio
January 2026

TRex Bio is a biotechnology company that treats diseases like cancer, fibrotic by studying human tissues.

Bioinformatics · South San Francisco$50.0M Series Unknown
XellSmart
January 2026

Xellsmart develops stem cell treatment solutions for a variety of degenerative diseases for which there are now no clinical treatments.

Biopharma · MinhangSeries C
Recludix Pharma
January 2026

Recludix pharma is a developing platform to treat cancer patients.

Biotechnology · San DiegoUndisclosed
ProQR Therapeutics
January 2026

ProQR Therapeutics is a biotech company focused on developments of drugs to treat genetic disorders.

Biotechnology · Leiden$9.2M Grant
InduPro
January 2026

InduPro deevlops proximity-based protein therapeutics that modulate cell-surface protein interactions to treat disease.

Biotechnology · SeattleCorporate Round
Sanegene Bio
December 2025

Sanegene Bio develops an RNAi drug discovery platform designed for unmet clinical needs.

Biopharma · Woburn$110.0M Series B
Excelsior Sciences
December 2025

Excelsior Sciences applies AI and automated chemistry to simplify small-molecule discovery and accelerate overall drug development.

Artificial Intelligence (AI) · New York$70.0M Series A
ABL Bio
November 2025

ABL Bio is a biotech research company that focuses on the development of therapeutic drugs for immuno-oncology diseases.

Biotechnology · Seongnam$15.2M Post Ipo Equity
Trogenix
October 2025

Trogenix is a biotech company that develops precision cancer treatments that selectively target diseased cell states and behaviour.

Biotechnology · Edinburgh$94.4M Series A
Crossbow Therapeutics
September 2025

Crossbow Therapeutics is a biotech company developing a new type of cancer treatment.

Biotechnology · Cambridge$30.3M Series Unknown
Volastra Therapeutics
September 2025

Volastra Therapeutics is a biotechnology company developing novel therapies for the treatment of metastatic cancers.

Biotechnology · New York$30.1M Series A

Where Eli Lilly invests

Biotechnology22
Health Care14
Life Science8
Therapeutics8
Medical8
Biopharma7

About Eli Lilly's portfolio

How many companies has Eli Lilly invested in?

Eli Lilly has invested in 158 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Eli Lilly invest in?

Eli Lilly's top investment sectors include Biotechnology, Health Care, Life Science, Therapeutics, Medical. The firm invests across 20 different industry categories.

What is Eli Lilly's largest investment?

Among tracked funding rounds, Sanegene Bio received $110.0M in a Series B round. Eli Lilly's total known invested capital is $7.3B.

What is the average investment size for Eli Lilly?

Eli Lilly's average investment size is $55.2M across its portfolio of 158 companies.

What are Eli Lilly's most recent investments?

Recent Eli Lilly portfolio additions include Juvena Therapeutics, Rimidi, Fountain Therapeutics, Rezo Therapeutics, Gate Bioscience. These companies were founded in 2020 or later.

Reach the founders behind these 158 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →